Thursday, November 23, 2017 2:10:50 PM
The Center for Medicare and Medicaid Services (CMS) released the final 2018 Clinical Laboratory Fee Schedule (CLFS) today, re-affirming the preliminary rate for AlloMap of $3,240, an increase of 14% compared with the 2017 CMS CLFS rate of $2,840.75. The higher 2018 reimbursement rate for AlloMap was due in part to effective claims management, which increased the weighted median of commercial reimbursement. This data was shared with CMS as required by regulations associated with the Protecting Access to Medicare Act of 2014 (PAMA). The effective date of the increase is January 1, 2018.
“The implementation of PAMA by CMS provides a refreshing predictability to the reimbursement of diagnostic tests,” said Sasha King, Chief Commercial Officer at CareDx. “The updated rate highlights the value AlloMap brings to heart transplant patients.”
About CareDx
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients. CareDx offers products across the transplant testing continuum, including AlloMap® and AlloSure™ for post-transplant surveillance and Olerup SSP®, Olerup QTYPE®, and Olerup SBT™ for pre-transplant HLA testing.
For more information, please visit: www.CareDx.com.
Recent CDNA News
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 05/09/2024 08:43:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:14:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:09:26 PM
- CareDx Reports First Quarter 2024 Results • Business Wire • 05/09/2024 08:05:00 PM
- CareDx Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 05/03/2024 08:10:00 PM
- CareDx to Report First Quarter 2024 Financial Results • Business Wire • 04/29/2024 08:05:00 PM
- CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/19/2024 08:05:00 PM
- CareDx Appoints John W. Hanna as its New President and Chief Executive Officer • Business Wire • 04/16/2024 08:02:00 PM
- CareDx et ses collaborateurs présentent les dernières avancées dans le domaine cardio-thoracique lors de la réunion 2024 de la Société internationale de transplantation cardiaque et pulmonaire • Business Wire • 04/09/2024 05:40:00 PM
- CareDx und Mitarbeiter präsentieren neueste Herz-Thorax-Fortschritte im Rahmen des 2024 International Society for Heart and Lung Transplantation Meeting • Business Wire • 04/09/2024 05:33:00 PM
- CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting • Business Wire • 04/09/2024 11:00:00 AM
- CareDx Appoints Bryan Riggsbee to Its Board of Directors • Business Wire • 03/11/2024 08:10:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 08:02:01 PM
- Form POSASR - Post-effective Amendment to an automatic shelf registration statement • Edgar (US Regulatory) • 02/28/2024 09:07:27 PM
- CareDx Announces Fourth Quarter and Full Year 2023 Financial Results • Business Wire • 02/28/2024 09:05:00 PM
- CareDx to Participate in the Raymond James & Associates’ 45th Annual Institutional Investors Conference • Business Wire • 02/27/2024 09:05:00 PM
- CareDx to Report Fourth Quarter and Full Year 2023 Financial Results • Business Wire • 02/21/2024 09:05:00 PM
- CareDx Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring at the 2024 Tandem Meetings • Business Wire • 02/21/2024 12:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 08:34:29 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 03:17:49 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/12/2024 10:48:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 11:33:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 02:29:57 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 02:24:16 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/05/2024 11:08:57 AM
FEATURED POET Announces Design Win and Collaboration with Foxconn Interconnect Technology for High-speed AI Systems • May 14, 2024 10:09 AM
FEATURED Element79 Gold Corp Reports Exceptionally High-Grade Results from Lucero • May 14, 2024 7:00 AM
VAYK Added New Manager for Expansion into $64 Billion Domestic Short-term Rental Market • VAYK • May 14, 2024 9:00 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM